Analysts’ Weekly Ratings Changes for Replimune Group (REPL)

A number of firms have modified their ratings and price targets on shares of Replimune Group (NASDAQ: REPL) recently:

• 8/12/2026 – Replimune Group had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 8/11/2026 – Replimune Group was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/7/2026 – Replimune Group was upgraded by Wedbush from “neutral” to “outperform”. They now have a $12.00 price target on the stock.
• 8/7/2026 – Replimune Group had its price target raised by JPMorgan Chase & Co. from $17.00 to $20.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Replimune Group was upgraded by Wolfe Research to “outperform”.
• 8/4/2026 – Replimune Group was upgraded by Leerink Partners from “market perform” to “outperform”. They now have a $17.00 price target on the stock, up from $11.00.
• 7/31/2026 – Replimune Group was upgraded by Wedbush from “neutral” to “outperform”. They now have a $12.00 price target on the stock, up from $9.00.
• 7/31/2026 – Replimune Group was upgraded by Piper Sandler from “hold” to “strong-buy”.
• 7/20/2026 – Replimune Group was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/2/2026 – Replimune Group was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/30/2026 – Replimune Group was upgraded by BMO Capital Markets from “underperform” to “outperform”. They now have a $16.00 price target on the stock.
• 6/30/2026 – Replimune Group had its price target raised by Wedbush from $6.00 to $9.00. They now have a “neutral” rating on the stock.
• 6/26/2026 – Replimune Group was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $17.00 price target on the stock.

Insider Activity

In other news, CEO Sushil Patel sold 39,341 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the sale, the chief executive officer directly owned 708,151 shares in the company, valued at approximately $9,184,718.47. The trade was a 5.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Luisa Hill sold 11,448 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,480.56. Following the completion of the sale, the chief financial officer directly owned 225,108 shares of the company’s stock, valued at $2,919,650.76. This trade represents a 4.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 91,124 shares of company stock valued at $1,149,244. Insiders own 5.40% of the company’s stock.

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.